2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

J. Vansteenkiste, L. Crinò, C. Dooms, J. Y. Douillard, C. Faivre-Finn, E. Lim, G. Rocco, S. Senan, P. van Schil, G. Veronesi, R. Stahel, S. Peters, E. Felip, Keith Kerr, Benjamin Besse, Wilfried Eberhardt, Martin Edelman, Tony Mok, Ken O'Byrne, Silvia NovelloLukas Bubendorf, Antonio Marchetti, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz-Ares, Egbert F. Smit, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Walter Weder, Dirk de Ruysscher, Cecile Le Pechoux, Paul de Leyn, Virginie Westeel

Research output: Contribution to journalArticlepeer-review

408 Scopus citations

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, earlystage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.

Original languageEnglish
Pages (from-to)1462-1474
Number of pages13
JournalAnnals of Oncology
Volume25
Issue number8
DOIs
StatePublished - Aug 2014

Keywords

  • Carcinoma, Non-Small-Cell Lung/diagnosis
  • Consensus
  • Cytodiagnosis/statistics & numerical data
  • Early Detection of Cancer
  • Humans
  • Lung Neoplasms/diagnosis
  • Monitoring, Physiologic/methods
  • Neoplasm Staging/methods
  • Pneumonectomy/methods
  • Radiosurgery/statistics & numerical data
  • Risk Assessment
  • Tomography, X-Ray Computed/statistics & numerical data

Fingerprint

Dive into the research topics of '2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up'. Together they form a unique fingerprint.

Cite this